0000883975 2025-01-01 2025-09-30 0000883975 2025-11-12 0000883975 2025-09-30 0000883975 2024-12-31 0000883975 2025-07-01 2025-09-30 0000883975 2024-07-01 2024-09-30 0000883975 2024-01-01 2024-09-30 0000883975 us-gaap:CommonStockMember 2023-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883975 us-gaap:RetainedEarningsMember 2023-12-31 0000883975 2023-12-31 0000883975 us-gaap:CommonStockMember 2024-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000883975 us-gaap:RetainedEarningsMember 2024-03-31 0000883975 2024-03-31 0000883975 us-gaap:CommonStockMember 2024-06-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000883975 us-gaap:RetainedEarningsMember 2024-06-30 0000883975 2024-06-30 0000883975 us-gaap:CommonStockMember 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-12-31 0000883975 us-gaap:CommonStockMember 2025-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000883975 us-gaap:RetainedEarningsMember 2025-03-31 0000883975 2025-03-31 0000883975 us-gaap:CommonStockMember 2025-06-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000883975 us-gaap:RetainedEarningsMember 2025-06-30 0000883975 2025-06-30 0000883975 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000883975 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000883975 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000883975 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000883975 2024-04-01 2024-06-30 0000883975 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000883975 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000883975 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000883975 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000883975 2025-01-01 2025-03-31 0000883975 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000883975 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000883975 2025-04-01 2025-06-30 0000883975 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000883975 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000883975 us-gaap:CommonStockMember 2024-09-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000883975 us-gaap:RetainedEarningsMember 2024-09-30 0000883975 2024-09-30 0000883975 us-gaap:CommonStockMember 2025-09-30 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000883975 us-gaap:RetainedEarningsMember 2025-09-30 0000883975 MBOT:AtTheMarketOfferingProgramMember 2025-01-01 2025-03-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-03-31 0000883975 us-gaap:PrivatePlacementMember 2025-04-01 2025-06-30 0000883975 us-gaap:PrivatePlacementMember 2025-07-01 2025-09-30 0000883975 us-gaap:MoneyMarketFundsMember 2025-09-30 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-09-30 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2025-09-30 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2025-09-30 0000883975 us-gaap:FairValueInputsLevel1Member 2025-09-30 0000883975 us-gaap:FairValueInputsLevel2Member 2025-09-30 0000883975 us-gaap:FairValueInputsLevel3Member 2025-09-30 0000883975 us-gaap:MoneyMarketFundsMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 MBOT:TwoThousandThirteenThroughJuneThirtyTwoThousandTwentyFiveMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-09-30 0000883975 MBOT:CardioSertLtdMember MBOT:IsraeliInnovationAuthorityMember 2022-10-06 2022-10-06 0000883975 srt:MinimumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-09-30 0000883975 srt:MaximumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-09-30 0000883975 srt:MinimumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 srt:MaximumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2021-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-07-01 2024-07-01 0000883975 2022-10-03 2022-10-03 0000883975 MBOT:HCWainwrightAndCoLLCMember 2022-10-03 2022-10-03 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2022-10-06 2022-10-06 0000883975 MBOT:DeviceMember 2022-10-06 2022-10-06 0000883975 MBOT:IntegratedProductMember 2022-10-06 2022-10-06 0000883975 MBOT:SecuritiesPurchaseAgreementMember 2025-01-01 2025-09-30 0000883975 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2023-12-31 0000883975 2023-01-01 2023-12-31 0000883975 MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 2025-03-01 2025-03-31 0000883975 MBOT:CertainEmployeesMember 2025-09-30 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 0000883975 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-06-10 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:PlacementAgentPreferredInvestmentOptionsMember 2025-06-10 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:PlacementAgentPreferredInvestmentOptionsMember 2025-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEPreferredInvestmentOptionsMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEPreferredInvestmentOptionsMember 2025-01-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEandSeriesFAndSeriesGPreferredInvestmentOptionsMember 2025-06-30 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0000883975 MBOT:SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember 2025-07-01 2025-09-30 0000883975 MBOT:SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember 2025-09-30 0000883975 us-gaap:PrivatePlacementMember 2025-07-01 2025-09-30 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 srt:ManagementMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-01-01 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-01-01 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-29 0000883975 MBOT:BoardMember 2025-02-01 2025-02-28 0000883975 MBOT:TwentyTwentyOmnibusPerformanceAwardPlanMember 2025-06-10 0000883975 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0000883975 MBOT:ExecutivesMember 2025-01-01 2025-09-30 0000883975 MBOT:CertainEmployeesAndCertainBoardMembersMember 2025-01-01 2025-09-30 0000883975 2025-08-01 2025-08-31 0000883975 2025-08-31 0000883975 2025-06-09 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesGPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesHPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesIPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 srt:MinimumMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 srt:MaximumMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:SeriesJPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 2025-09-14 0000883975 MBOT:SeriesJPreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-14 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:TheLetterAgreementMember 2025-09-16 2025-09-16 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:SecondClosingMember MBOT:TheLetterAgreementMember 2025-09-29 2025-09-29 0000883975 MBOT:WainwrightMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2025-09-30 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuary2024Member 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantSeriesFJune2024Member 2025-09-30 0000883975 MBOT:WarrantSeriesFJune2024Member 2024-12-31 0000883975 MBOT:WarrantSeriesFJune2024Member 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember 2025-09-30 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2025-09-30 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2025-09-30 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesJSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-09-30 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2025-09-30 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember 2025-01-01 2025-09-30 0000883975 us-gaap:AllOtherSegmentsMember 2025-07-01 2025-09-30 0000883975 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0000883975 us-gaap:AllOtherSegmentsMember 2025-01-01 2025-09-30 0000883975 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0000883975 2025-07-01 2025-07-31 0000883975 MBOT:PreferredInvestmentOptionsMember MBOT:ThirdClosingMember us-gaap:SubsequentEventMember MBOT:TheLetterAgreementMember 2025-10-06 2025-10-06 iso4217:USD shares iso4217:USD shares MBOT:Segment iso4217:ILS pure iso4217:ILS shares false --12-31 Q3 0000883975 10-Q true 2025-09-30 2025 false 000-19871 MICROBOT MEDICAL INC. DE 94-3078125 175 Derby St., Bld. 27 Hingham MA 02043 (781) 875-3605 Common Stock MBOT NASDAQ Yes Yes Non-accelerated Filer true false false 67158044 0.01 6704000 3114000 73454000 2356000 54000 49000 573000 300000 80785000 5819000 78000 80000 897000 132000 81760000 6031000 509000 165000 297000 70000 2128000 2225000 2934000 2460000 602000 41000 3536000 2501000 0.01 0.01 120000000 60000000 65833556 65833556 19399513 19399513 659000 195000 178187000 94279000 -100622000 -90944000 78224000 3530000 81760000 6031000 1171000 2060000 4741000 4646000 2690000 1240000 5864000 3549000 -3861000 -3300000 -10605000 -8195000 316000 284000 85000 611000 144000 -3577000 -3215000 -9678000 -8051000 -0.07 -0.07 -0.20 -0.20 -0.25 -0.25 -0.53 -0.53 48095384 48095384 16471419 16471419 38618642 38618642 15129574 15129574 11707317 118000 83884000 -79501000 4501000 1685682 17000 2380000 2397000 1005965 10000 1101000 1111000 529000 529000 -2371000 -2371000 14398964 145000 87894000 -81872000 6167000 1566669 16000 2006000 2022000 331000 331000 -2465000 -2465000 15965633 161000 90231000 -84337000 6055000 685800 7000 678000 685000 283000 283000 -3215000 -3215000 16651433 168000 91192000 -87552000 3808000 19399513 195000 94279000 -90944000 3530000 13891840 139000 25778000 25917000 842606 8000 989000 997000 610517 6000 846000 852000 256000 256000 -2601000 -2601000 34744476 348000 122148000 -93545000 28951000 3213840 32000 4474000 4506000 163000 163000 237000 237000 -3500000 -3500000 37958316 380000 127022000 -97045000 30357000 37958316 380000 127022000 -97045000 30357000 15063395 151000 26708000 26859000 12664627 127000 24129000 24256000 100000 1000 47218 1000 1000 328000 328000 -3577000 -3577000 65833556 659000 178187000 -100622000 78224000 65833556 659000 178187000 -100622000 78224000 333000 328000 49000 2683000 65000 64000 340000 12000 1954000 2249000 153000 -9678000 -8051000 37000 65000 282000 2000 821000 1067000 175000 274000 -11000 -176000 -1335000 -1100000 -9288000 -7136000 35000 18000 79918000 5120000 9102000 2680000 2500000 -70851000 42000 83733000 5104000 1000 83734000 5104000 3595000 -1990000 3163000 2517000 6758000 527000 893000 37000 153000 1111000 76000 30000 6704000 479000 54000 48000 6758000 527000 <p id="xdx_802_eus-gaap--NatureOfOperations_zrps4By4hcXd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82F_zQyEWKdrlkV5">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Description of business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Inc. (the “Company”) is a medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incorporated on <span id="xdx_908_edei--EntityIncorporationDateOfIncorporation_c20250101__20250930_z9AIv5i1H4Ok" title="Date of incorporation">August 2, 1988</span> in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel” or “Subsidiary”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 78pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its Subsidiary are sometimes collectively referred to as the “Company” as the context may require.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Risk Factors </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated revenues from its operations. As of September 30, 2025, the Company had cash equivalents and marketable securities balance of approximately $<span id="xdx_902_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20250930_z2CaiszNIBhj" title="Cash equivalents and marketable securities">80,158</span>, excluding restricted cash. Due to continuing research and development and pre-commercialization activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company’s management has concluded that the available funds as of the balance sheet date, are sufficient to fund the Company’s operations for more than twelve months from the issuance date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may raise additional funds through future issuances of either debt and/or equity securities, including pursuant to a possible At-the-Market offering, upon cash exercise of outstanding investment options, and additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Israel-Hamas War</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel’s subsequent military operations in Syria, and the escalation of military operations by and against the Houthis in Yemen and the Iranian regime, are on-going as of the issuance date of these financial statements, although there have been cease fires and lulls in military operations from time to time, including the most recent cease-fire with Hamas on October 10, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has considered various ongoing risks relating to the military operations and related matters, including:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That some of our Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, may not be fully active and operational, as instructed by the relevant authorities;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A slowdown in the number of international flights in and out of Israel;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decreasing international regard for Israeli-based companies in certain quarters, including as a result of the Israeli government’s policies in Gaza and the West Bank; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible and actual boycotts of Israel and Israeli-based companies, which may adversely affect the Company’s ability to do business in certain jurisdictions or with certain industry groups or potential customers, among others.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is closely monitoring how the military operations and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct its devices and to ship them outside of Israel. As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations, but the Company continues to monitor the situation, as any collapse of a cease-fire with any nation or group hostile to Israel from time to time, or any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support its clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Unaudited Interim Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim consolidated condensed financial statements should be read in conjunction with the Company’s latest audited financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for the three and nine-month period ended September 30, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1988-08-02 80158000 <p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zCj7WmO6OXwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_820_zYx8VT5pEuN3">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company’s latest annual audited financial statements, except if noted below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zwCr9K4bzTr5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2J7E03GCFV1">Basis of presentation</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zmd7WlEI5BO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUFkGO0tDMW1">Use of estimates</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP0KbcTuWaS3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zhvCsfX7MXzd">Fair value of financial instruments</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1 </b>- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b> - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMLKAQxIWPcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2025, and December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zDXEhVfiiFBd" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250930_zOeJHwa3ZA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCm35mdnx0u9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTO5T8rPQYMi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZo06gWGPBC3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z9M0CQf2clTj" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zn7i3Uj6Ika" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z090KpuucGGc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zg5yb8j6P38b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUjXga4aelYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvvQWP4ON20b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Marketable securities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zXrxbzj3Xk06" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zpx46gFA2yF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z7npvdXY3Mbe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of September 30, 2025 and December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zL6tB9SXvave" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zRL6Ma3HuLoc">Share-based compensation</span>: </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwEeaCoHYof2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDEdAj4TRQOe">Recently adopted accounting pronouncements</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. The ASU was effective for the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent interim periods. As part of the Annual Report for the year ended December 31, 2024, the Company adopted ASU 2023-07, which was applied retrospectively to all prior periods presented. Refer to Note 5 herein for further details regarding this adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--AccountingPronouncementsNotYetEffectivePolicyTextBlock_zpW3GjFwZ3T4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z0KXB6EiMa6g">Accounting pronouncements not yet effective</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.</span></p> <p id="xdx_85C_z1isXV2kAyQ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zwCr9K4bzTr5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2J7E03GCFV1">Basis of presentation</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zmd7WlEI5BO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUFkGO0tDMW1">Use of estimates</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP0KbcTuWaS3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zhvCsfX7MXzd">Fair value of financial instruments</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1 </b>- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b> - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMLKAQxIWPcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2025, and December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zDXEhVfiiFBd" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250930_zOeJHwa3ZA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCm35mdnx0u9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTO5T8rPQYMi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZo06gWGPBC3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z9M0CQf2clTj" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zn7i3Uj6Ika" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z090KpuucGGc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zg5yb8j6P38b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUjXga4aelYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvvQWP4ON20b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Marketable securities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zXrxbzj3Xk06" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zpx46gFA2yF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z7npvdXY3Mbe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of September 30, 2025 and December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMLKAQxIWPcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2025, and December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zDXEhVfiiFBd" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250930_zOeJHwa3ZA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCm35mdnx0u9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTO5T8rPQYMi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZo06gWGPBC3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z9M0CQf2clTj" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">73,454</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zn7i3Uj6Ika" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z090KpuucGGc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zg5yb8j6P38b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUjXga4aelYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvvQWP4ON20b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Marketable securities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zXrxbzj3Xk06" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zpx46gFA2yF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities</span> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 73454000 73454000 73454000 73454000 2356000 2356000 2356000 2356000 <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zL6tB9SXvave" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zRL6Ma3HuLoc">Share-based compensation</span>: </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwEeaCoHYof2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDEdAj4TRQOe">Recently adopted accounting pronouncements</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. The ASU was effective for the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent interim periods. As part of the Annual Report for the year ended December 31, 2024, the Company adopted ASU 2023-07, which was applied retrospectively to all prior periods presented. Refer to Note 5 herein for further details regarding this adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--AccountingPronouncementsNotYetEffectivePolicyTextBlock_zpW3GjFwZ3T4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z0KXB6EiMa6g">Accounting pronouncements not yet effective</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.</span></p> <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zuqjXZs3JSLa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_823_z2JPmUhuKfa5">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Government grants:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Israel has received grants from the IIA for participation in research and development since 2013 through September 30, 2025, totaling approximately $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20250101__20250930__us-gaap--AwardDateAxis__custom--TwoThousandThirteenThroughJuneThirtyTwoThousandTwentyFiveMember__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zIEiQbENFSDj" title="Revenue grants received">2,154</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $<span id="xdx_90E_ecustom--RepaymentOfGovernmentGrants_pn3n3_c20221006__20221006__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__us-gaap--BusinessAcquisitionAxis__custom--CardioSertLtdMember_zsdzqVpLvIcg" title="Repayment of government grants">925</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to <span id="xdx_902_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20250930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zybgVmtOw1c8" title="Net sales royalty percenatge">3.0</span>% - <span id="xdx_90E_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20250930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_ztqSQH6VcFxd" title="Net sales royalty percenatge">5</span>% of its future sales of the products up to grant amount plus interest. The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of Secured Overnight Financing Rate (“SOFR”) per year (SOFR is a benchmark interest rate which replaced LIBOR).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project- by-project basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, the Company received a grant from the Ministry of Economy, in the amount of approximately $<span id="xdx_902_eus-gaap--GrantsReceivable_iI_c20250930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zOH7JTsNqXH">50 for participation in expenses related to the LIBERTY^® Endovascular Robotic Surgical System in the U.S. market. In relation with the Ministry of Economy grant, the Company is obligated to pay royalties amounting to </span></span><span id="xdx_904_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20250930_zlyzrDYUHZOi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span>% of future sales of the LIBERTY^® Endovascular Robotic Surgical System up to the grant amount plus interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. TRDF agreement:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to its then Self-Cleaning Shunt (“SCS”) project and TipCat assets, which also governed certain technology relating to the Company’s LIBERTY^®Endovascular Robotic Surgical System. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between <span id="xdx_90F_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MinimumMember_zMur1vluQrVk" title="Net sales">1.5</span>%-<span id="xdx_90F_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MaximumMember_zU4ybjm6uh5d" title="Net sales royalty percenatge">3.0</span>%) and on sublicense income as detailed in the License Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023 and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY^® Endovascular Robotic Surgical System.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. ATM agreement:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright &amp; Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $<span id="xdx_90E_ecustom--OfferingCosts_iI_pn3n3_c20210610__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zzmAbnnkm4Jl" title="Offering costs">10,000</span> at market prices or as otherwise agreed with Wainwright. The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zUABoHWwAErl" title="Aggregate offering">4,820</span> from time to time through Wainwright, acting as sales agent. The compensation to Wainwright for sales of the shares is a placement fee of <span id="xdx_902_ecustom--PlacementFeePercent_pid_dp_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zUkEFAqPRWxl" title="Percentage of placement fee">3.0</span>% of the gross sales price of the shares of common stock sold pursuant to this ATM Agreement. See also Note 4B below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Engagement letters with H.C. Wainwright:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023, and on May 29, 2024 which was amended most recently on February 9, 2025, in each case pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to <span id="xdx_906_ecustom--GrossProceedsFromCashFeePercentage_pid_dp_c20221003__20221003_zojP4YDCcDVc" title="Gross proceeds from cash fee percentage">7.0</span>% of the gross proceeds received by the Company from offerings contemplated by the Engagement Letters, plus a management fee equal to <span id="xdx_901_ecustom--GrossProceedsFromManagementFeePercentage_pid_dp_c20221003__20221003_zEikNAkrjU2" title="Gross proceeds from management fee percentage">1.0</span>% of the gross proceeds received by the Company from such offerings, as well as other reimbursable expenses. <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20221003__20221003__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zvTcnqlzpcq4" title="Warrant issued, descriptions">The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings. In addition, upon exercise for cash of any investment options by an investor, the Company has agreed to pay Wainwright a cash fee equal to 7.0% of the gross proceeds from such exercise and to issue to Wainwright or its designees additional preferred investment options equal to five (5.0%) percent of the aggregate number of shares of common stock issued upon such exercise See also Note 4C below.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E. Acquisition of Nitiloop’s assets:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20221006__20221006__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zThMMzY95le1" title="Stock issued during period, value, new issues">8,000</span>, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties at a rate of <span id="xdx_905_ecustom--RoyaltiesPercentage1_pid_dp_uPure_c20221006__20221006__srt--ProductOrServiceAxis__custom--DeviceMember_zWKNxAPJHQSj" title="Royalties percentage">3</span>% of net revenue generated as a result of sales, license or other exploitation of the Devices; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties at a rate of <span id="xdx_903_ecustom--RoyaltiesPercentage1_pid_dp_uPure_c20221006__20221006__srt--ProductOrServiceAxis__custom--IntegratedProductMember_zG7vlXXNcucj" title="Royalties percentage">1.5</span>% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as part of an integrated product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. Litigation resulting from the 2017 financing:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017, equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB4JiYKwhMZ6" title="Purchase price of plaintiffs">6,750</span> purchase price with respect to the 2017 Financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Settlement Agreement, the Company paid $<span id="xdx_90C_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240126__20240126_zAtsRrYZ0ivc" title="Litigation settlement amount">2,154</span> consisting of a cash payment of $<span id="xdx_901_eus-gaap--PaymentsForLegalSettlements_pn3n3_c20240126__20240126__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zhySC37Amp0f" title="Payment for litigation settlement">1,100</span>, covered by the Company’s insurance company, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240126__20240126__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_z9NYcrDGhk" title="Restricted common shares issued for legal settlement">1,005,965</span> shares of restricted common stock which were subsequently registered for resale. Furthermore, the Company’s insurance company is responsible for covering legal expenses incurred by the Company in relation to the legal proceedings of the Lawsuit. In February 2024, the Plaintiffs filed a stipulation discontinuing the Lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a current liability and a current asset on its consolidated balance sheet totaling $<span id="xdx_90C_eus-gaap--LiabilitiesCurrent_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zYoAgKoNJ1J" title="Liabilities current">2,211</span> and $<span id="xdx_905_eus-gaap--AssetsCurrent_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zAX8nzu4CZMh" title="Assets current">1,335</span>, respectively. Within this asset, $<span id="xdx_909_eus-gaap--LossContingencyReceivable_iI_pn3n3_c20231231_zeo8z0s08014" title="Settlement amount recovery">1,100</span> represents the recovery of the cash payment of the settlement amount, and $<span id="xdx_902_eus-gaap--LegalFees_pn3n3_c20230101__20231231_zZVMKdqeZPIa" title="Legal expense">235</span> represents recovery of legal expenses. A net non-operating loss of $<span id="xdx_908_eus-gaap--GainLossRelatedToLitigationSettlement_iN_pn3n3_di_c20230101__20231231_zMreIIEN3K23" title="Non operating loss on legal settlement">1,111</span> from legal settlement was reflected in the Company’s consolidated statement of comprehensive loss for the year ended December 31, 2023. In the first quarter of 2024, the Company received $<span id="xdx_902_ecustom--InsuranceRecoveryAmount_pn3n3_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zveZZMhyGl25" title="Insurance recovery amount">1,335</span> from the insurance company. Additionally, during the first quarter of 2024, the Company paid the settlement amount by transferring $<span id="xdx_90C_eus-gaap--PaymentsForLegalSettlements_pn3n3_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_zj1CeYuzBUei" title="Payment for litigation settlement">1,100</span> in cash to the Plaintiffs and issuing <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zywabB7iWC76" title="Number of share issued">1,005,965</span> shares of the Company’s common stock, thereby settling the liability recorded as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G. Mona litigation:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2025, an appellate court held in favor of the Company with respect to a 2019 action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. As a result, the Company received a judgment in the amount of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromLegalSettlements_pn3n3_c20250301__20250331_zwh0VWFv2T8c" title="Net proceeds">316</span>, net of legal fees and expenses. The amount received was recorded as other income in the Company’s interim condensed consolidated statement of comprehensive loss. A subsequent petition by the defendant to the United States Supreme Court for review to overturn the appellate court’s ruling has been denied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H. Employment-Related Matter</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 17, 2025, the Company received a demand letter from legal counsel representing a former employee in connection with an employment-related matter. As of the issuance date of these financial statements, the Company has not received a formal notice or service of a claim from any government agency or with respect to any court, tribunal or panel. Based on its initial assessment, the Company believes the claims are without merit. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I. Accrued bonuses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, the Company recorded accrued bonuses to the CEO and other executives, in the aggregate amount of $<span id="xdx_90B_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_pn3n3_c20250930__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_z3PEgKJAwssg" title="Accrued bonuses">535</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2154000 925000 0.030 0.05 0.03 0.015 0.030 10000000 4820000 0.030 0.070 0.010 The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings. In addition, upon exercise for cash of any investment options by an investor, the Company has agreed to pay Wainwright a cash fee equal to 7.0% of the gross proceeds from such exercise and to issue to Wainwright or its designees additional preferred investment options equal to five (5.0%) percent of the aggregate number of shares of common stock issued upon such exercise See also Note 4C below. 8000000 0.03 0.015 6750000 2154000 1100000 1005965 2211000 1335000 1100000 235000 -1111000 1335000 1100000 1005965 316000 535000 <p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zsOYlMHmlWf1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span><span id="xdx_825_zmWl69KtHYmf">SHARE CAPITAL</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Registered direct and private placement offerings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVnjzidh62Cb" title="Shares issued">4,000,001</span> shares of the Company’s common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKToT0Utb9rf" title="Common stock, par value">0.01</span> per share, at an offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjivx858IDQg">1.75</span> per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250106__20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjuMsi3t8XA7" title="Placement agent fee">7,000</span> before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpwYwxEomrm4" title="Offering expense">690</span>. In a concurrent private placement, the Company agreed to issue to the investors series G preferred investment options to purchase up to <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_zWgzYRHsMTLk" title="Shares issued">8,000,002</span> shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsFToXjrWBk" title="Exercise price">1.75</span> per share. Each Series G preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zzVjtNPo0Wyf" title="Options purchased">200,000</span> shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zTPyQkawDfW9" title="Share price">2.1875</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 7, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmFsYSqnoqSj" title="Shares issued">3,788,550</span> shares of the Company’s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrsZDAZonGS4" title="Common stock, par value">0.01</span> per share, at an offering price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9omzMO3mR9">2.27</span> per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250107__20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCc68oRTkhd">8,600</span> before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6EBZJQjdjB1" title="Offering expense">818</span>. In a concurrent private placement, the Company agreed to issue to the investors series H preferred investment options to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_zNzBHMHloQxl" title="Shares issued">7,577,100</span> shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zim0YtkIvS9e" title="Exercise price">2.10</span> per share. Each Series H preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zvxsIM5fJxph" title="Options purchased">189,428</span> shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_z285vphtrRf1" title="Share price">2.8375</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 9, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHGJKO556RKj" title="Shares issued">6,103,289</span> shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6u4cM5qKT6" title="Common stock, par value">0.01</span> per share, at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zordXK3Ee8Ve">2.13</span> per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250209__20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOuWszmhoul1">13,000</span> before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk7YJeUkLkvj" title="Offering expense">1,175</span>. In a concurrent private placement, the Company agreed to issue to the investors series I preferred investment options to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zO4Pzn6TnOc8" title="Shares issued">12,206,578</span> shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY2FcvKceBZ" title="Exercise price">2.13</span> per share. Each Series I preferred investment option is exercisable on the later of (i) the date on which the amendment to the Company’s articles of incorporation that increases the number of authorized shares of common stock to an amount of shares of common stock sufficient for the exercise in full of the series I preferred investment options is filed and accepted with the State of Delaware law (such date, the “Authorized Share Increase Date”) and (ii) the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to the issuance of all the series I preferred investment options and the shares of common stock issuable upon the exercise thereof, is received and deemed effective under Delaware law (the “Initial exercise date”), and will expire two years from the initial exercise date. Net cash settlements are not permitted under any event under the Securities Purchase Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_ztnRlwc8fHje">305,164</span> shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zwHF3WbNc9F5" title="Share price">2.6625</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2025, at the Company’s annual meeting of stockholders, an amendment to the Company’s articles of incorporation was approved, increasing the number of authorized shares of common stock to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250610_zcJ3yqk9RHN1" title="Common stock, shares authorized">120,000,000</span>. The amendment was subsequently filed with and accepted by the State of Delaware law and became effective on that date. Refer to Note 4G.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, the Series I preferred investment options to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250610__20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zMnyTf7aMS7c">12,206,578</span> shares of common stock at an exercise price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_z4zumnu76tej" title="Share price">2.13</span> per share, and the placement agent preferred investment options to purchase up to <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250610__20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zXrwlNdmHgvk">305,164</span> shares of common stock at an exercise price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z2S3GjiwP4d3" title="Share price">2.6625</span> per share, each of which was issued on February 11, 2025, became immediately exercisable until their two year anniversary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. At-the-market offerings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zEiEeRRnogRf">4,820</span> of the Company’s shares of common stock pursuant to the ATM Agreement. During the fiscal year ended December 31, 2024, the Company issued<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zo6fLc9hNpa4"> 3,433,880</span> shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zGlnSOYNciHb" title="Total gross proceeds">3,756</span> before deducting sales agent commissions and other offering expenses of $<span id="xdx_90E_eus-gaap--OtherExpenses_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zpx8sDiVeDC8" title="Other offering expenses">239</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zzpnrxmht9H4" title="Shares issued">842,606</span> shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z6sz5HBOTIr9" title="Total gross proceeds">1,062</span> before deducting sales agent commissions and other offering expenses of $<span id="xdx_903_eus-gaap--OtherExpenses_pn3n3_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zrxNNSLNfiDf" title="Other offering expenses">65</span>. The Company is no longer selling its securities pursuant to the ATM Agreement and has not as of the filing of these financial statements entered into a new or replacement ATM agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Exercise of Investment Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company raised approximately $<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20250101__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_zLogkECjDyTf" title="Gross proceeds from option exercise">916</span> in gross proceeds from the exercise of an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_zNzt9vpNs8D" title="Number of options outstanding">610,517</span> outstanding Series E preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company paid a cash fee of approximately $<span id="xdx_908_eus-gaap--PaymentsForFees_pn3n3_c20250101__20250131__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zLkhhVviVzu9" title="Cash fee">64</span> to its placement agent and issued an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zwNxeT8ZlyE9" title="Options issued">30,526</span> placement agent options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">During the three months ended June 30, 2025, the Company raised approximately $<span id="xdx_90B_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20250401__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesEandSeriesFAndSeriesGPreferredInvestmentOptionsMember_zU3MeJDAaJs9" title="Gross proceeds from option exercise">5,021 in gross proceeds from the exercise of an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesEandSeriesFAndSeriesGPreferredInvestmentOptionsMember_z0mnUgAASsy6" title="Number of options outstanding">3,313,840</span> outstanding Series E, Series F and Series G preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company paid a cash fee of approximately $<span id="xdx_904_eus-gaap--PaymentsForFees_pn3n3_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_z7rHdP3ULffj" title="Cash fee">352</span> to its placement agent and issued an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_z4RGx3URf2Sd" title="Options issued">165,693</span> placement agent options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 30, 2025, the Company raised approximately $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember_zVA2lzDtv55h" title="Gross proceeds from option exercise">27,918</span> in gross proceeds from the exercise of an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesEGHIAndSeriesFPreferredInvestmentOptionsMember_zb5hPW3vhtJf" title="Number of options outstanding">14,689,228</span> outstanding Series E, Series F, Series G, Series H and Series I preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company paid a cash fee of approximately $<span id="xdx_904_eus-gaap--PaymentsForFees_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_z0ELxqAzlfAk" title="Cash fee">1,954</span> to its placement agent and issued an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zKezLw3y8155" title="Options issued">734,461</span> placement agent options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company received gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zZsZpIgPNu2a" title="Proceeds from options">895</span> from the exercise of an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--PrivatePlacementMember_zq09TrVoA8S6" title="Number of shares issued">374,167</span> outstanding placement agent </span>options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Equity classification</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock of the Company is classified as equity under the requirements of ASC Topic 505 Equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzed the accounting treatment for all of the outstanding preferred investment options. Based on the Company’s analysis all such preferred investment options were classified as equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzed the accounting treatment for all of the outstanding preferred investment options issued to Wainwright. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E. Employee Stock Option Grants and Exercises</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted the CEO, its executives and management, fully vested options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKxAa86eDP44" title="Agggregate number of options granted">80,000</span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zPs4wB6SVpK1" title="Agggregate number of options granted">50,000</span> shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zHdyavMGan96" title="Weighted-average exercise price per share, granted">1.2684</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted the CEO and certain executives, options to purchase an aggregate of <span id="xdx_90D_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zvoDJh4zivP6" title="Additional number of stock options granted">80,000</span> and <span id="xdx_902_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zW7xfaLPWWO5" title="Additional number of stock options granted">52,500</span> shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_z4bO8WaXMnL6" title="Share price per share">1.25</span>. The vesting of these options is subject to the achievement of specified performance conditions. For the year ended December 31, 2024, the Company recorded an expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_z87yHUmggxc2" title="Compensation expenses">38</span>, reflecting management’s assessment that the specified performance milestones for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zE9lkwUZbp" title="Issued shares">35,625</span> of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zPt66fvDPra6" title="Agggregate number of options granted">132,500</span> options were achieved by their due date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted the CEO, its executives, and certain employees, options to purchase an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndExecutivesMember_zqa4jvpSUEul" title="Agggregate number of options granted">80,000</span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_zHOOIQ3Fh1dk" title="Agggregate number of options granted">115,000</span> shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_zCFJILLxGcR4" title="Share price per share">1.2684</span>, with a vesting period of three years.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted an advisor options to purchase an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zeC79ZI80uqe" title="Agggregate number of options granted">25,000 </span>shares of the Company’s common stock, at an exercise price per share of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zB0zs0WV0kW" title="Share price per share">0.881</span>, with a vesting period of three years.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to the CEO’s 2023 annual bonus, during February 2024, the Company paid <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWhbtnp7Kbh4" title="Compensation percentage">25</span>% of the CEO’s total 2023 bonus - amounting to approximately $<span id="xdx_903_ecustom--AnnualBonus_pn3n3_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCCBkO0PqZpd" title="Annual bonus">99</span>, through the grant of fully vested options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_znLZSB1kJDJ8" title="Agggregate number of options granted">79,567</span> shares of the Company’s common stock with an exercise price per share of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFMm8vqpLhOb" title="Share price per share">1.25</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2025, the Company determined that <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_z3Q5nSlBfJfc">35,625</span> out of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zBhAF9J4jG01">132,500</span> performance-based options granted in February 2024 had met their milestones and been vested, while the remainder <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zGfOxkIn2PBk">96,875</span> options which did not meet their milestones had been forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2025, at the Company’s annual meeting of stockholders, an amendment to the Company’s 2020 Omnibus Performance Award Plan (as amended) was approved. This amendment increased the number of shares of common stock authorized and reserved for issuance under the plan by <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250610__us-gaap--PlanNameAxis__custom--TwentyTwentyOmnibusPerformanceAwardPlanMember_zw0W2pVJzAcg" title="Common stock capital shares reserved for future issuance">2,591,019</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2025, the Company granted the CEO, executives and certain employees, and certain board members, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhcqjwDZT4D6">228,000</span>, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__srt--TitleOfIndividualAxis__custom--ExecutivesMember_zQkIv2WFLir6">386,375</span> and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__srt--TitleOfIndividualAxis__custom--CertainEmployeesAndCertainBoardMembersMember_zpCHyF9IdAxb">70,000</span> options, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">In August 2025, a former advisor of the Company exercised <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20250801__20250831_zv3EUfjxSl86" title="Options vested">47,218</span> vested options at an exercise price of NIS <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uILSPShares_c20250831_zl9bwTRdcLSc" title="Options vested exercise price">0.01</span> per option. As a result of this exercise, the Company received total consideration of approximately $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250801__20250831_z6fbBDC0gEU2" title="Options vested value">1</span>. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. Warrants:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgngFcHhjDql" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remaining outstanding warrants and terms as of September 30, 2025 and December 31, 2024, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zY6vi58ny3Y3" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and<br/> exercisable as of <br/> September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and <br/> exercisable as of<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Through</b></span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Warrant to underwriters October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zzGBiCakegj3" style="width: 12%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zBsfHGY40Dy2" style="width: 12%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_znoyPCd6VVSb" style="width: 12%; text-align: right" title="Exercise price">6.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zPS6c4VOLLKe" title="Exercisable Through">October 21, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zWziZinReDuc" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zwE4re7Cucyf" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_znpqMV0qzbo3" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zeetMnPuDWY4" title="Exercisable Through">November 23, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_z7sOITvoRlPl" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zsFWZLzHw9ub" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zmMQWvzntaY9" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zV5kA10D2nT5" title="Exercisable Through">November 24, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zhfoUY9PXNvj" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zA786t14gXK6" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_z5eWcslIIobf" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zd0aXXHWYpj8" title="Exercisable Through">June 2, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z5VNFbXBVPCb" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zqoBDn0U1ZKj" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z31cZszXGxj3" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z0gsus7i1Osa" title="Exercisable Through">June 28, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zW84UVZoSq14" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zOWix5nVPd92" style="margin: 0" title="Number of outstanding warrants">1,685,682</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zClb0SZfGjP4" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zG3nRLak28N2" title="Exercisable Through">July 3, 2029</span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zmY4KFa33Uv1" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zRxUdQjr21j5" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zSWgjbuYHtx6" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z0YxUe96zowb" title="Exercisable Through">July 3, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_z1QPtb1yEbb2" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zvlocXgq1ux9" style="margin: 0" title="Number of outstanding warrants">3,133,338</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right" title="Exercise price"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zAQJl8i2q9Yd" style="margin: 0" title="Exercise price">1.50</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zqp8K7rwmFQa" title="Exercisable Through">June 3, 2026</span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zeJPKtUQynja" style="text-align: right" title="Number of outstanding warrants">28,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zf2b7xHtqjJe" style="text-align: right" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zxENJcrsGL6h" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z13NK0aDN15k" title="Exercisable Through">June 3, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series H January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zSiecXQnrT7f" style="text-align: right" title="Number of outstanding warrants">1,324,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zzAA5mCGVYh5" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_ztAA2BPY1mfj" style="text-align: right" title="Exercise price">2.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zhl9eFXC7uTf" title="Exercisable Through">January 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zjeH6r4ik4k4" style="text-align: right" title="Number of outstanding warrants">71,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zwz4KJctKGu1" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zBSQ7k9q9Zue" style="text-align: right" title="Exercise price">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zSU11V7lpmP2" title="Exercisable Through">January 7, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zUzlBGdZHTCb" style="text-align: right" title="Number of outstanding warrants">189,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zigOv29cZOug" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zYWHbaAJUh68" style="text-align: right" title="Exercise price">2.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zgec6goiKoF8" title="Exercisable Through">January 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zsdB8nkHHk42" style="text-align: right" title="Number of outstanding warrants">30,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zA62FOQJMJxi" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zHJ3MHWKH2B9" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zMoscsQhZY3i" title="Exercisable Through">July 8, 2030</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters February 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zMIDI1wa57gd" style="text-align: right" title="Number of outstanding warrants">109,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zdoBJ35RQdm9" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zOLhDGVoxUFc" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zEDWQGFBVR5d" title="Exercisable Through">June 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zE63xjJUGD34" style="text-align: right" title="Number of outstanding warrants">10,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zWu7O3xZC9v7" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zqAPbT6jf5Ck" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zvRPj1ENPBXf" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zn5wQHVKutNd" style="text-align: right" title="Number of outstanding warrants">31,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zxf3E4QfEWFe" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_z7MJ5qG1gOXd" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zps6LAvAfd66" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zpMaQhgQJBsl" style="text-align: right" title="Number of outstanding warrants">138,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_z27F6M9FGGha" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zuoeewAZSALj" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_z5yK6eZToG1g" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zaWcvazgOGgb" style="text-align: right" title="Number of outstanding warrants">422,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zBCAF4zLTPwd" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zflV0a6w6ng5" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zjsOggI0lQn6" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zjPNIduCrmC3" style="text-align: right" title="Number of outstanding warrants">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zKojyjbuRRN6" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zC5vdnYi6IRg" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zGrMVvUzAOQ7" title="Exercisable Through">March 29, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zLvicosmxcCk" style="text-align: right" title="Number of outstanding warrants">53,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zV3iKUSUHOS8" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zNApgFa66sq8" style="text-align: right" title="Exercise price">1,88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zYbvjiMQOxN1" title="Exercisable Through">March 16, 2031</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zLCILHagGADe" style="text-align: right" title="Number of outstanding warrants">146,306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zEnbm4O4zWe6" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zBgmoW7l8e65" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zkbVNNdvABhb" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z3JP8AaO6mr" style="text-align: right" title="Number of outstanding warrants">368,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zCUPoAGZWu9a" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zyhyKVuI4MVi" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zpdmFopLGNB7" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_z3ynMfyH0ZE5" style="text-align: right" title="Number of outstanding warrants">143,723</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zyxje8m4DqKj" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zKrTBLlcedq5" style="text-align: right" title="Exercise price">2.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zmtBQ1MjPSM" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zeJU0s77vDK9" style="text-align: right" title="Number of outstanding warrants">187,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zeJkIUDsa2Oi" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zn2a05Eq0Hea" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zRDEGiB9uX4g" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zYJGQcDWeRo5" style="text-align: right" title="Number of outstanding warrants">12,064,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zoASnwsdW0c3" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zUYb7BpmVxzf" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zimPZ8e7Aome" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zqeYQS1S7037" style="margin: 0" title="Number of outstanding warrants">600,000</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z5yeXjSWFasf" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><p style="margin: 0">$</p></td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zirbkHQOFmkf" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z4SMCUIlTFN8" title="Exercisable Through">March 29, 2028</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr> </table> <p id="xdx_8A2_z3mLCZKXMihi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G. Increase in Authorized Shares:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2025, following the stockholders approval obtained at the 2025 annual meeting of stockholders of the Company, the Company filed with the State of Delaware a certificate of amendment to the Company’s restated certificate of incorporation, as amended, which increased the total number of shares of common stock authorized for issuance to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250610_zbtWaoFfHDCb" title="Common stock, shares authorized">120,000,000</span> shares, with a corresponding increase in the total authorized shares from <span id="xdx_903_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250609_z5XCGxRZnKH4" title="Total authorized shares">61,000,000</span> to <span id="xdx_905_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250610_zWcrppXmH46g" title="Total authorized shares">121,000,000</span>. Immediately thereafter, the Company had <span id="xdx_905_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250610_zqDvZL5yFhZ8" title="Total authorized shares">121,000,000</span> shares of authorized stock, consisting of (i) <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250610_zVzRDwEpuCol" title="Common stock, shares authorized">120,000,000</span> shares of common stock, and (ii) <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250610_zOtHEzUvYdD7" title="Preferred stock, shares authorized">1,000,000</span> shares of undesignated preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H. Investment Inducement Transaction:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2025, the Company entered into an inducement agreement (the “Letter Agreement”) with certain holders (the “Holders”) of existing (i) series F preferred investment options to purchase <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zkHHrzbAwzs">207,224</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock at an exercise price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zXT7ZsnOvAsj">1.50</span> per share, (ii) series G preferred investment options to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_zWkQOUJtRyz8">628,571</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_z9IvBQrK7OS7">1.75</span> per share, (iii) series H preferred investment options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_z04xEsfcRbFi">4,702,612</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_ze4nMClIzZ5j">2.10</span> per share, and (iv) series I preferred investment options to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zlePv319h0ic">8,450,708</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock at an exercise price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zgicdxDcnQd3">2.13</span> per share (collectively, the “Existing Preferred Investment Options”). Pursuant to the Letter Agreement, the Holders exercised for cash their Existing Preferred Investment Options to purchase an aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember_zhhgGuRyFkl4">13,989,115</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock, at exercise prices ranging from $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__srt--RangeAxis__srt--MinimumMember_zurE562kkpg7">1.50</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zQxdrLb2Oiji">2.13</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, in consideration for the Company’s agreement to issue new series J preferred investment options (the “New Preferred Investment Options”) to purchase up to an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250914__20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredInvestmentOptionsMember_z7tYXGoEeO5">13,989,115</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20250914__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredInvestmentOptionsMember_zEBFAmJwUJpg">4.50</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (collectively, the “Inducement Transaction”). The New Preferred Investment Options are exercisable beginning six months after issuance and will expire two years thereafter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the first closing of the Inducement Transaction, which occurred on September 16, 2025, certain Holders exercised Existing Preferred Investment Options to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zZeuyusbxLK4">12,064,627</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock for cash and received New Preferred Investment Options to purchase up to an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zW7IYjfhf5n6">12,064,627</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock. At the second closing of the Inducement Transaction on September 29, 2025, a certain Holder exercised Existing Preferred Investment Options to purchase <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SecondClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zxr4LSGC6ZU6">600,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock for cash and received New Preferred Investment Options to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SecondClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember_zx2lPEnIt0l5">600,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The third closing of the Inducement Transaction occurred on October 6, 2025. Refer to Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received aggregate gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromOtherEquity_pn5n6_c20250101__20250930_zadPoxTkGyR6" title="Proceeds from exercise of PIOs">26,505</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> from the exercise of the Existing Preferred Investment Options at the closings, before deducting placement agent fees and other offering expenses of approximately $<span id="xdx_904_ecustom--InducementTransactionCost_c20250930_zDCou66Xn36l" title="Inducement transaction cost">2,249</span>, of which $<span id="xdx_90C_ecustom--UnpaidAmount_iI_c20250930_zrOr51ycpf65" title="Unpaid amount">153 </span>had not been paid as of September 30, 2025. Additionally, as a result of the Inducement Transaction, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company issued an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__srt--TitleOfIndividualAxis__custom--WainwrightMember_zwXc2ZH15yLb" title="Issued shares">633,232</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">placement agent options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4000001 0.01 1.75 7000000 690000 8000002 1.75 200000 2.1875 3788550 0.01 2.27 8600000 818000 7577100 2.10 189428 2.8375 6103289 0.01 2.13 13000000 1175000 12206578 2.13 305164 2.6625 120000000 12206578 2.13 305164 2.6625 4820000 3433880 3756000 239000 842606 1062000 65000 916000 610517 64000 30526 3313840 352000 165693 27918000 14689228 1954000 734461 895000 374167 80000 50000 1.2684 80000 52500 1.25 38000 35625 132500 80000 115000 1.2684 25000 0.881 0.25 99000 79567 1.25 35625 132500 96875 2591019 228000 386375 70000 47218 0.01 1 <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgngFcHhjDql" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remaining outstanding warrants and terms as of September 30, 2025 and December 31, 2024, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zY6vi58ny3Y3" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and<br/> exercisable as of <br/> September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and <br/> exercisable as of<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Through</b></span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Warrant to underwriters October 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zzGBiCakegj3" style="width: 12%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zBsfHGY40Dy2" style="width: 12%; text-align: right" title="Number of outstanding warrants">51,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_znoyPCd6VVSb" style="width: 12%; text-align: right" title="Exercise price">6.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zPS6c4VOLLKe" title="Exercisable Through">October 21, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zWziZinReDuc" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zwE4re7Cucyf" style="text-align: right" title="Number of outstanding warrants">32,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_znpqMV0qzbo3" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeMember_zeetMnPuDWY4" title="Exercisable Through">November 23, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters May 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_z7sOITvoRlPl" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zsFWZLzHw9ub" style="text-align: right" title="Number of outstanding warrants">60,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zmMQWvzntaY9" style="text-align: right" title="Exercise price">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersMayTwoThousandTwentyThreeOneMember_zV5kA10D2nT5" title="Exercisable Through">November 24, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zhfoUY9PXNvj" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zA786t14gXK6" style="text-align: right" title="Number of outstanding warrants">35,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_z5eWcslIIobf" style="text-align: right" title="Exercise price">2.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeMember_zd0aXXHWYpj8" title="Exercisable Through">June 2, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z5VNFbXBVPCb" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_zqoBDn0U1ZKj" style="text-align: right" title="Number of outstanding warrants">31,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z31cZszXGxj3" style="text-align: right" title="Exercise price">4.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyThreeOneMember_z0gsus7i1Osa" title="Exercisable Through">June 28, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series E January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zW84UVZoSq14" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zOWix5nVPd92" style="margin: 0" title="Number of outstanding warrants">1,685,682</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zClb0SZfGjP4" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuary2024Member_zG3nRLak28N2" title="Exercisable Through">July 3, 2029</span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zmY4KFa33Uv1" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zRxUdQjr21j5" style="text-align: right" title="Number of outstanding warrants">84,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zSWgjbuYHtx6" style="text-align: right" title="Exercise price">2.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_z0YxUe96zowb" title="Exercisable Through">July 3, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series F June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_z1QPtb1yEbb2" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zvlocXgq1ux9" style="margin: 0" title="Number of outstanding warrants">3,133,338</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right" title="Exercise price"><p id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zAQJl8i2q9Yd" style="margin: 0" title="Exercise price">1.50</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJune2024Member_zqp8K7rwmFQa" title="Exercisable Through">June 3, 2026</span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters June 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zeJPKtUQynja" style="text-align: right" title="Number of outstanding warrants">28,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zf2b7xHtqjJe" style="text-align: right" title="Number of outstanding warrants">78,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zxENJcrsGL6h" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z13NK0aDN15k" title="Exercisable Through">June 3, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series H January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zSiecXQnrT7f" style="text-align: right" title="Number of outstanding warrants">1,324,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zzAA5mCGVYh5" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_ztAA2BPY1mfj" style="text-align: right" title="Exercise price">2.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandandTwentyFiveMember_zhl9eFXC7uTf" title="Exercisable Through">January 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zjeH6r4ik4k4" style="text-align: right" title="Number of outstanding warrants">71,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zwz4KJctKGu1" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zBSQ7k9q9Zue" style="text-align: right" title="Exercise price">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zSU11V7lpmP2" title="Exercisable Through">January 7, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zUzlBGdZHTCb" style="text-align: right" title="Number of outstanding warrants">189,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zigOv29cZOug" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zYWHbaAJUh68" style="text-align: right" title="Exercise price">2.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zgec6goiKoF8" title="Exercisable Through">January 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters January 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zsdB8nkHHk42" style="text-align: right" title="Number of outstanding warrants">30,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zA62FOQJMJxi" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zHJ3MHWKH2B9" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zMoscsQhZY3i" title="Exercisable Through">July 8, 2030</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters February 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zMIDI1wa57gd" style="text-align: right" title="Number of outstanding warrants">109,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zdoBJ35RQdm9" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zOLhDGVoxUFc" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zEDWQGFBVR5d" title="Exercisable Through">June 10, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zE63xjJUGD34" style="text-align: right" title="Number of outstanding warrants">10,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zWu7O3xZC9v7" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zqAPbT6jf5Ck" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveMember_zvRPj1ENPBXf" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zn5wQHVKutNd" style="text-align: right" title="Number of outstanding warrants">31,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zxf3E4QfEWFe" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_z7MJ5qG1gOXd" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveOneMember_zps6LAvAfd66" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zpMaQhgQJBsl" style="text-align: right" title="Number of outstanding warrants">138,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_z27F6M9FGGha" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_zuoeewAZSALj" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveTwoMember_z5yK6eZToG1g" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zaWcvazgOGgb" style="text-align: right" title="Number of outstanding warrants">422,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zBCAF4zLTPwd" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zflV0a6w6ng5" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveThreeMember_zjsOggI0lQn6" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zjPNIduCrmC3" style="text-align: right" title="Number of outstanding warrants">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zKojyjbuRRN6" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zC5vdnYi6IRg" style="text-align: right" title="Exercise price">2.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFourMember_zGrMVvUzAOQ7" title="Exercisable Through">March 29, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zLvicosmxcCk" style="text-align: right" title="Number of outstanding warrants">53,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zV3iKUSUHOS8" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zNApgFa66sq8" style="text-align: right" title="Exercise price">1,88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveFiveMember_zYbvjiMQOxN1" title="Exercisable Through">March 16, 2031</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zLCILHagGADe" style="text-align: right" title="Number of outstanding warrants">146,306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zEnbm4O4zWe6" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zBgmoW7l8e65" style="text-align: right" title="Exercise price">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSixMember_zkbVNNdvABhb" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_z3JP8AaO6mr" style="text-align: right" title="Number of outstanding warrants">368,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zCUPoAGZWu9a" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zyhyKVuI4MVi" style="text-align: right" title="Exercise price">2.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveSevenMember_zpdmFopLGNB7" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_z3ynMfyH0ZE5" style="text-align: right" title="Number of outstanding warrants">143,723</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zyxje8m4DqKj" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zKrTBLlcedq5" style="text-align: right" title="Exercise price">2.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveEightMember_zmtBQ1MjPSM" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant to underwriters September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zeJU0s77vDK9" style="text-align: right" title="Number of outstanding warrants">187,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zeJkIUDsa2Oi" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zn2a05Eq0Hea" style="text-align: right" title="Exercise price">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersSeptemberTwoThousandTwentyFiveNineMember_zRDEGiB9uX4g" title="Exercisable Through">September 16, 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zYJGQcDWeRo5" style="text-align: right" title="Number of outstanding warrants">12,064,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zoASnwsdW0c3" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zUYb7BpmVxzf" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJSeptemberTwoThousandTwentyFiveMember_zimPZ8e7Aome" title="Exercisable Through">March 16, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant series J September 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Number of outstanding warrants"><p id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zqeYQS1S7037" style="margin: 0" title="Number of outstanding warrants">600,000</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z5yeXjSWFasf" style="text-align: right" title="Number of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span><p style="margin: 0"></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><p style="margin: 0">$</p></td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_zirbkHQOFmkf" style="text-align: right" title="Exercise price">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><p style="margin: 0"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesJOneSeptemberTwoThousandTwentyFiveMember_z4SMCUIlTFN8" title="Exercisable Through">March 29, 2028</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr> </table> 51125 51125 6.11 October 21, 2027 32778 32778 2.75 November 23, 2026 60476 60476 2.75 November 24, 2026 35088 35088 2.67 June 2, 2028 31231 31231 4.06 June 28, 2028 1685682 1.50 July 3, 2029 84284 84284 2.03 July 3, 2029 3133338 1.50 June 3, 2026 28102 78333 1.88 June 3, 2026 1324488 2.10 January 10, 2027 71750 2.19 January 7, 2027 189428 2.84 January 10, 2027 30526 1.88 July 8, 2030 109478 2.66 June 10, 2027 10362 1.88 March 16, 2028 31429 2.12 March 16, 2028 138906 2.62 March 16, 2028 422535 2.66 March 16, 2028 30000 2.62 March 29, 2028 53758 1.88 March 16, 2031 146306 1.88 September 16, 2027 368572 2.12 September 16, 2027 143723 2.63 September 16, 2027 187794 2.66 September 16, 2027 12064627 4.50 March 16, 2028 600000 4.50 March 29, 2028 120000000 61000000 121000000 121000000 120000000 1000000 207224 1.50 628571 1.75 4702612 2.10 8450708 2.13 13989115 1.50 2.13 13989115 4.50 12064627 12064627 600000 600000 26505000000 2249 153 633232 <p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zUN32gVI7dld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_826_zEpLeruWzk6e">SEGMENT REPORTING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment information is prepared on the same basis that the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_zZL9gGKm3RLi" title="Number of operating segments"><span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20250930_zqMAsSVV0tbc" title="Number of reportable segments">one</span></span> operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents and marketable securities. The chief executive officer performs the assessment of segment performance by using the reported measure of segment loss to monitor actual results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zTP29PJoj2Wf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and nine months ended September 30, 2025, and 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zxrQTjjg5yrd" style="display: none">SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zrizjNTzuHSc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_z1oZcCaNaT7a" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zqSpPij6HSk7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zg2Uxtvi80g6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Significant segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_z7XTKlA6TDG2" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,035</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,391</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,159</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,575</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zZJSy6YL2Mx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">954</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,597</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zfQ0sZz25Izj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_zs3f3DcgbEJj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other segment items (<span id="xdx_F4F_zoy7PXqYUwme">*</span>)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">635</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">587</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,176</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zj4TOSuUUBZk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,051</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span id="xdx_F07_zuNHe5Dscq1c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zH8seqxAaV4c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1 1 <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zTP29PJoj2Wf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and nine months ended September 30, 2025, and 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zxrQTjjg5yrd" style="display: none">SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zrizjNTzuHSc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_z1oZcCaNaT7a" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zqSpPij6HSk7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zg2Uxtvi80g6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Significant segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_z7XTKlA6TDG2" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Payroll and payroll related</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,035</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,391</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,159</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,575</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zZJSy6YL2Mx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Materials and subcontractors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">954</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,597</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zfQ0sZz25Izj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_zs3f3DcgbEJj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other segment items (<span id="xdx_F4F_zoy7PXqYUwme">*</span>)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">635</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">587</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,176</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zj4TOSuUUBZk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,051</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span id="xdx_F07_zuNHe5Dscq1c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zH8seqxAaV4c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2035000 1391000 5159000 3575000 579000 954000 1522000 1597000 -328000 -283000 -821000 -1067000 -635000 -587000 -2176000 -1812000 3577000 3215000 9678000 8051000 <p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_z1L4fLMMavVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_823_zivTyd0uI8Qg">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2025, the Company entered into a lease agreement for its US office for the period from March 2025 until February 2027. The monthly lease payments are approximately $<span id="xdx_903_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_c20250301__20250331_zmiSJx4JB7If" title="Finance lease principal payments">2</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2025, the Subsidiary entered into a lease agreement for its Israel office for the period from July 2025 until October 2029. The monthly lease payments are approximately $<span id="xdx_905_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_c20250701__20250731_zJ4rmJHAtq3l">19</span>. To secure the lease payments, the Company issued a bank guarantee of $<span id="xdx_905_ecustom--BankGuaranteeIssued_pn3n3_c20250701__20250731_zHY17wHcPGL1">54</span> in favor of the facility’s lessor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has several agreements for car leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zonifJuu1Nsb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease obligations under our non-cancelable lease agreements as of September 30, 2025 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zY1C1zC83ibh" style="display: none">SCHEDULE OF MINIMUM LEASE OBLIGATION</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250930_zDB5DZP2Srid" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzDag_zLhapk79SdYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_zd6m7iptdzi8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zRj75D2UWGoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">247</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDag_zUWKcumTmD47" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzDag_zekufm21XQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">189</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zA70WIJ1qHX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zVgrU7It1Luk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(145</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zTowUxQngnNc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">899</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z209vA5TXyH2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--LeaseCostTableTextBlock_zryMaZPhTNGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes the weighted-average lease terms and discount rates for operating leases as of September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zhna2wON7SH">SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating leases weighted average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20250930_zPZrznCCbUe9" title="Operating leases weighted average remaining lease term (in years)">3.82</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250930_zGs37wlbhnok" style="text-align: right" title="Operating leases weighted average discount rate">8.13</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_zVEgpFOHvfr5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zrvT9CNZZME9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the nine and three months ended September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zWAZ8j1wsDg2" style="display: none">SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20250701__20250930_zn60RCjVem0d" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20250101__20250930_zThYvPDtj526" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_zRZSRAmBpNm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating lease expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zAWDR7tAAAH5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zesfU2VJPAl2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases for the nine months ended September 30, 2025 as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zHqv3pyKwVa9" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20250101__20250930_zYId5cHBXgn2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasePayments_pn3n3_zRLbMJOe6Xoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Cash paid under operating lease agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zyLIuXm2boyb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">893</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zYHjDbmT3j8l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2000 19000 54000 <p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zonifJuu1Nsb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease obligations under our non-cancelable lease agreements as of September 30, 2025 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zY1C1zC83ibh" style="display: none">SCHEDULE OF MINIMUM LEASE OBLIGATION</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250930_zDB5DZP2Srid" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzDag_zLhapk79SdYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDag_zd6m7iptdzi8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDag_zRj75D2UWGoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">247</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDag_zUWKcumTmD47" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzDag_zekufm21XQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">189</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDag_zA70WIJ1qHX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zVgrU7It1Luk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(145</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zTowUxQngnNc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">899</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 81000 298000 247000 229000 189000 1044000 145000 899000 <p id="xdx_892_eus-gaap--LeaseCostTableTextBlock_zryMaZPhTNGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes the weighted-average lease terms and discount rates for operating leases as of September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zhna2wON7SH">SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating leases weighted average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20250930_zPZrznCCbUe9" title="Operating leases weighted average remaining lease term (in years)">3.82</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250930_zGs37wlbhnok" style="text-align: right" title="Operating leases weighted average discount rate">8.13</td><td style="text-align: left">%</td></tr> </table> P3Y9M25D 0.0813 <p id="xdx_890_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zrvT9CNZZME9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the nine and three months ended September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zWAZ8j1wsDg2" style="display: none">SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20250701__20250930_zn60RCjVem0d" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20250101__20250930_zThYvPDtj526" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_zRZSRAmBpNm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating lease expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191</td><td style="width: 1%; text-align: left"> </td></tr> </table> 94000 191000 <p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zesfU2VJPAl2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases for the nine months ended September 30, 2025 as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zHqv3pyKwVa9" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20250101__20250930_zYId5cHBXgn2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasePayments_pn3n3_zRLbMJOe6Xoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Cash paid under operating lease agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zyLIuXm2boyb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">893</td><td style="text-align: left"> </td></tr> </table> 129000 893000 <p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zdoWIDeWZTmc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7– <span id="xdx_823_zQL95K9vqmx5">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On October 6, 2025, in connection with the third closing of the Inducement Transaction, the Company received aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--PaymentsForProceedsFromInvestments_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0shxY28T75a" title="Proceeds from investments">2,781</span> from the exercise of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ZP6TctSX2e" title="New shares issued">1,324,488</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Preferred Investment Options and issued an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwqauxm20S3l" title="New shares issued for services">1,324,488</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Preferred Investment Options to purchase up to an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20251006__20251006__us-gaap--TypeOfArrangementAxis__custom--TheLetterAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--ThirdClosingMember__us-gaap--AwardTypeAxis__custom--PreferredInvestmentOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt2hyoeRH1Ra" title="New shares purchased">1,324,488</span> shares of the Company’s common stock.</span></p> 2781 1324488 1324488 1324488 false false false false false false false false Less than $1. Net of issuance costs in the amount of $333. See Note 3F. Net of issuance costs in the amount of $328. Net of issuance costs in the amount of $49. Net of issuance costs in the amount of $2,683. Net of issuance costs in the amount of $65. Net of issuance costs in the amount of $64. Net of issuance costs in the amount of $340. Net of issuance costs in the amount of $12. Net of issuance costs in the amount of $1,954. Net of issuance costs in the amount of $2,249, of which $153 had not been paid as of September 30, 2025. Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.